Apoptosis-based anticancer drugs

Nature Reviews Drug Discovery

Volumn 1, Issue 2, 2002, Pages 101-102

  Zhang, Jason Y ^a  

^a Research Analyst in Biopharmaceuticals at Stephens Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; DRUG EFFECT; GENE THERAPY; HUMAN; MUTATION; NEOPLASM; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; GENE THERAPY; GENES, BCL-2; GENES, P53; HUMANS; MUTATION; NEOPLASMS;

EID: 0036463370     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd742     Document Type: Note

References (5)

1. Jansen, B, et ai. Chemosensitisation of malignant meianoma by BCL2 antisense therapy. Lancet 356, 1728-1733(2000).
2. Clayman, G. L, etal. Adenovirus-mediated p53genetransfer in patients with advanced recurrent head and neck squamous cell cardnoma. J. Clin. Oncol. 16, 2221-2232 (1998).
3. Swisher, S, G, etal. Induction of pro-apoptotic mecliators and tumor regression foiiowing intratumoral delivery of adenoviral p53 (RPR/INGN201) and radiatiori therapy in patients with non-smali-ceii iung cancer, Proc. Am. Soc. Clin. Oncol. 20, A1024 (2001).
4. Buiier, R. E. etal. Muiti-closeintraperitoneal (IP) RAD/p53 (SCH58500) gene replacement combined with chemotherapy in heavily pretreatecl recurrent ovarian cancer is assodatecl with prolonged survival, Proc. Am. Soc. Clin. Oncol. 20, A1047 (2001).
5. Khuri, F. R, etal. A coritrollecl trial of intratumoral ONYX-015, a selectively replicating acieriovims, in combination with dsplatin and 5-fluorouradl in patients with recurrent head and neck cancer, Nature Med. 6, 879-885 (2000).